Abstract
BackgroundEstablished biomarkers of immune checkpoint inhibitor (ICI) response in metastatic non-small cell lung cancer (mNSCLC), such as PD-L1 and tumor mutational burden (TMB), do not identify all patients with durable...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have